Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies ...

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...

The Swedish drugmaker has come up short in its effort to push imlifidase into treatment of the autoimmune condition ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...

As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is ...

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Andrew Willett discussed the path that led him to Lundbeck and ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...